[
    {
        "Publi_ID": "Pub_000001",
        "Year": 2020,
        "Authors": [
            "Xiaolei Pei",
            "Wenwei Shao",
            "Allene Xing",
            "Charles Askew",
            "Xiaojing Chen",
            "Caibin Cui",
            "Yasmina L Abajas",
            "David A Gerber",
            "Elizabeth P Merricks",
            "Timothy C Nichols",
            "Wuping Li",
            "R Jude Samulski",
            "Chengwen Li"
        ],
        "Title": "Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity.",
        "Journal": "Mol Ther Methods Clin Dev",
        "DOI": "10.1016/j.omtm.2020.06.003",
        "Keywords": [
            "AAV",
            "Nabs",
            "chimeric mice",
            "human hepatocyte",
            "tropism"
        ],
        "Pages": 10,
        "Abstract": "Adeno-associated virus (AAV) vectors have been successfully used in patients with bleeding disorders and blindness. For human liver targeting, two major factors restrict effective AAV transduction after systemic administration of AAV vectors: human hepatocyte tropism and neutralizing antibodies (Nabs). In this study, we attempted to isolate AAV variants with the ability to transduce human hepatocytes and escape Nabs using a directed evolution approach ",
        "Total_word_count": 5482,
        "AAV_count": 335,
        "Frequency": 0.0611090843,
        "Linked_references": [
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578.",
            "Hurlbut, G.D., Ziegler, R.J., Nietupski, J.B., Foley, J.W., Woodworth, L.A., Meyers, E., Bercury, S.D., Pande, N.N., Souza, D.W., Bree, M.P., et al. (2010). Preexisting immu- nity and low expression in primates highlight translational challenges for liver- directed AAV8-mediated gene therapy. Mol. Ther. 18, 1983–1994.",
            "Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C.J., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. Mol. Ther. 24, 1042–1049.",
            "Wang, L., Bell, P., Somanathan, S., Wang, Q., He, Z., Yu, H., McMenamin, D., Goode, T., Calcedo, R., and Wilson, J.M. (2015). Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids. Mol. Ther. 23, 1877–1887.",
            "Paulk, N.K., Pekrun, K., Zhu, E., Nygaard, S., Li, B., Xu, J., Chu, K., Leborgne, C., Dane, A.P., Haft, A., et al. (2018). Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity. Mol. Ther. 26, 289–303.",
            "Pekrun, K., De Alencastro, G., Luo, Q.J., Liu, J., Kim, Y., Nygaard, S., Galivo, F., Zhang, F., Song, R., Tiffany, M.R., et al. (2019). Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, 131610.",
            "Meliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018). Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat. Commun. 9, 4098.",
            "Mingozzi, F., Anguela, X.M., Pavani, G., Chen, Y., Davidson, R.J., Hui, D.J., Yazicioglu, M., Elkouby, L., Hinderer, C.J., Faella, A., et al. (2013). Overcoming pre- existing humoral immunity to AAV using capsid decoys. Sci. Transl. Med. 5, 194ra92.",
            "Gao, K., Li, M., Zhong, L., Su, Q., Li, J., Li, S., He, R., Zhang, Y., Hendricks, G., Wang, J., and Gao, G. (2014). Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side- Effects. Mol. Ther. Methods Clin. Dev. 1, 20139.",
            "Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti- adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods 24, 59–67.",
            "Velazquez, V.M., Meadows, A.S., Pineda, R.J., Camboni, M., McCarty, D.M., and Fu, H. (2017). Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting. Mol. Ther. Methods Clin. Dev. 4, 159–168.",
            "Corti, M., Elder, M., Falk, D.J., Lawson, L., Smith, B.K., Nayak, S., Conlon, T.J., Clément, N., Erger, K., Lavassani, E., et al. (2014). B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Mol. Ther. Methods Clin. Dev. 1, 14033.",
            "Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.F., Moullier, P., Benveniste, O., and Masurier, C. (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19, 2084–2091.",
            "Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in hemo- philia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347.",
            "Chai, Z., Samulski, R.J., and Li, C. (2018). Nab Escaping AAV Mutants Isolated from Mouse Muscles. Bio Protoc. 8, e2841.",
            "Bowles, D.E., McPhee, S.W., Li, C., Gray, S.J., Samulski, J.J., Camp, A.S., Li, J., Wang, B., Monahan, P.E., Rabinowitz, J.E., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 20, 443–455.",
            "Albright, B.H., Storey, C.M., Murlidharan, G., Castellanos Rivera, R.M., Berry, G.E., Madigan, V.J., and Asokan, A. (2018). Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Mol. Ther. 26, 510–523.",
            "Gray, S.J., Blake, B.L., Criswell, H.E., Nicolson, S.E., Samulski, R.J., McCown, T.J., and Li, W. (2010). Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol. Ther. 18, 570–578."
        ],
        "AAV_terms": [
            "AAV",
            "AAV8",
            "AAV9",
            "AAV6",
            "AAV2",
            "AAV1",
            "AAV3",
            "AAV7",
            "AAV-mediated",
            "AAV9-PHP",
            "AAV/luc",
            "AAV/GFP",
            "AAVs",
            "AAVrh10",
            "AAV1/AAV6",
            "AAV/LUC",
            "AAV8-mediated",
            "AAV-Factor",
            "AAVrh"
        ],
        "PMCID": "PMC7329936",
        "PMID": "32637455"
    },
    {
        "Publi_ID": "Pub_000002",
        "Year": 2017,
        "Authors": [
            "D G Hickey",
            "T L Edwards",
            "A R Barnard",
            "M S Singh",
            "S R de Silva",
            "M E McClements",
            "J G Flannery",
            "M W Hankins",
            "R E MacLaren"
        ],
        "Title": "Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina.",
        "Journal": "Gene Ther",
        "DOI": "10.1038/gt.2017.85",
        "Keywords": [],
        "Pages": 14,
        "Abstract": "There is much debate on the adeno-associated virus (AAV) serotype that best targets specific retinal cell types and the route of surgical delivery-intravitreal or subretinal. This study compared three of the most efficacious AAV vectors known to date in a mouse model of retinal degeneration (rd1 mouse) and macaque and human retinal explants. Green fluorescent protein (GFP) driven by a ubiquitous promoter was packaged into three AAV capsids: AAV2/8(Y733F), AAV2/2(quad Y-F) and AAV2/2(7m8). Overall, AAV2/2(7m8) transduced the largest area of retina and resulted in the highest level of GFP expression, followed by AAV2/2(quad Y-F) and AAV2/8(Y733F). AAV2/2(7m8) and AAV2/2(quad Y-F) both resulted in similar patterns of transduction whether they were injected intravitreally or subretinally. AAV2/8(Y733F) transduced a significantly smaller area of retina when injected intravitreally compared with subretinally. Retinal ganglion cells, horizontal cells and retinal pigment epithelium expressed relatively high levels of GFP in the mouse retina, whereas amacrine cells expressed low levels of GFP and bipolar cells were infrequently transduced. Cone cells were the most frequently transduced cell type in macaque retina explants, whereas Müller cells were the predominant transduced cell type in human retinal explants. Of the AAV serotypes tested, AAV2/2(7m8) was the most effective at transducing a range of cell types in degenerate mouse retina and macaque and human retinal explants.",
        "Total_word_count": 8256,
        "AAV_count": 298,
        "Frequency": 0.0360949612,
        "Linked_references": [
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17: 463–471.",
            "De Silva SR, Charbel Issa P, Singh MS, Lipinski DM, Barnea-Cramer AO, Walker NJ et al. Single residue AAV capsid mutation improves transduction of photo- receptors in the Abca4-/- mouse and bipolar cells in the rd1 mouse and human retina ex-vivo. Gene Therapy 2016; 23: 767–774.",
            "Macé E, Caplette R, Marre O, Sengupta A, Chaffiol A, Barbe P et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. Mol Ther 2014; 23: 7–16.",
            "Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther 2017; 28: 154–167.",
            "Watanabe S, Sanuki R, Ueno S, Koyasu T, Hasegawa T, Furukawa T. Tropisms of AAV for subretinal delivery to the neonatal mouse retina and its application for in vivo rescue of developmental photoreceptor disorders. PLoS ONE 2013; 8: e54146.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009; 17: 2096–2102.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17: 463–471.",
            "De Silva SR, Charbel Issa P, Singh MS, Lipinski DM, Barnea-Cramer AO, Walker NJ et al. Single residue AAV capsid mutation improves transduction of photo- receptors in the Abca4-/- mouse and bipolar cells in the rd1 mouse and human retina ex-vivo. Gene Therapy 2016; 23: 767–774.",
            "Macé E, Caplette R, Marre O, Sengupta A, Chaffiol A, Barbe P et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. Mol Ther 2014; 23: 7–16.",
            "Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther 2017; 28: 154–167.",
            "Watanabe S, Sanuki R, Ueno S, Koyasu T, Hasegawa T, Furukawa T. Tropisms of AAV for subretinal delivery to the neonatal mouse retina and its application for in vivo rescue of developmental photoreceptor disorders. PLoS ONE 2013; 8: e54146.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009; 17: 2096–2102.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther 2017; 28: 154–167.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther 2017; 28: 154–167.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther 2017; 28: 154–167.",
            "Petrs-Silva H, Dinculescu A, Li Q, Deng W-T, Pang J-J, Min S-H et al. Novel prop- erties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011; 19: 293–301.",
            "Vandenberghe LH, Bell P, Maguire AM, Cearley CN, Xiao R, Calcedo R et al. Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med 2011; 3: 88ra54.",
            "Petrs-Silva H, Dinculescu A, Li Q, Min S-H, Chiodo V, Pang J-J et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 2009; 17: 463–471.",
            "De Silva SR, Charbel Issa P, Singh MS, Lipinski DM, Barnea-Cramer AO, Walker NJ et al. Single residue AAV capsid mutation improves transduction of photo- receptors in the Abca4-/- mouse and bipolar cells in the rd1 mouse and human retina ex-vivo. Gene Therapy 2016; 23: 767–774.",
            "Macé E, Caplette R, Marre O, Sengupta A, Chaffiol A, Barbe P et al. Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. Mol Ther 2014; 23: 7–16.",
            "Ramachandran PS, Lee V, Wei Z, Song JY, Casal G, Cronin T et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther 2017; 28: 154–167.",
            "Watanabe S, Sanuki R, Ueno S, Koyasu T, Hasegawa T, Furukawa T. Tropisms of AAV for subretinal delivery to the neonatal mouse retina and its application for in vivo rescue of developmental photoreceptor disorders. PLoS ONE 2013; 8: e54146.",
            "Yin L, Greenberg K, Hunter JJ, Dalkara D, Kolstad KD, Masella BD et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 2011; 52: 2775–2783.",
            "Dalkara D, Kolstad KD, Caporale N, Visel M, Klimczak RR, Schaffer DV et al. Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous. Mol Ther 2009; 17: 2096–2102."
        ],
        "AAV_terms": [
            "AAV",
            "AAV2/8(Y733F)",
            "AAV2/2(quad Y-F)",
            "AAV2/2(7m8)",
            "AAV2/2",
            "AAV2/8",
            "AAV2/5",
            "AAV2/9",
            "AAV2/2(Y272, 444, 500, 730F)",
            "AAV-GFP",
            "AAV2/2(7 m8)",
            "AAV2/2(quadY-F)",
            "AAV2/2(7m8)-GFP",
            "AAV2/8(Y733F)-GFP",
            "AAV2/2(quad Y-F)-GFP",
            "AAV2",
            "AAV2-4YF-CMV-GFP",
            "AAV7m8",
            "AAV2-",
            "AAV8BP2",
            "AAV8",
            "AAV-mediated"
        ],
        "PMCID": "PMC5746594",
        "PMID": "28872643"
    },
    {
        "Publi_ID": "Pub_000003",
        "Year": 2019,
        "Authors": [
            "Katja Pekrun",
            "Gustavo De Alencastro",
            "Qing-Jun Luo",
            "Jun Liu",
            "Youngjin Kim",
            "Sean Nygaard",
            "Feorillo Galivo",
            "Feijie Zhang",
            "Ren Song",
            "Matthew R Tiffany",
            "Jianpeng Xu",
            "Matthias Hebrok",
            "Markus Grompe",
            "Mark A Kay"
        ],
        "Title": "Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors.",
        "Journal": "JCI Insight",
        "DOI": "10.1172/jci.insight.131610",
        "Keywords": [
            "Diabetes",
            "Embryonic stem cells",
            "Gene therapy",
            "Therapeutics"
        ],
        "Pages": 18,
        "Abstract": "While gene transfer using recombinant adeno-associated viral (rAAV) vectors has shown success in some clinical trials, there remain many tissues that are not well transduced. Because of the recent success in reprogramming islet-derived cells into functional β cells in animal models, we constructed 2 highly complex barcoded replication competent capsid shuffled libraries and selected for high-transducing variants on primary human islets. We describe the generation of a chimeric AAV capsid (AAV-KP1) that facilitates transduction of primary human islet cells and human embryonic stem cell-derived β cells with up to 10-fold higher efficiency compared with previously studied best-in-class AAV vectors. Remarkably, this chimeric capsid also enabled transduction of both mouse and human hepatocytes at very high levels in a humanized chimeric mouse model, thus providing a versatile vector that has the potential to be used in both preclinical testing and human clinical trials for liver-based diseases and diabetes.",
        "Total_word_count": 8407,
        "AAV_count": 295,
        "Frequency": 0.0350898061,
        "Linked_references": [
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "15;58(2):313–323.  18. Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-",
            "06;55(4):875–884.  20. Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.",
            "15;58(2):313–323.  18. Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-",
            "06;55(4):875–884.  20. Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "15;58(2):313–323.  18. Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-",
            "06;55(4):875–884.  20. Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19.",
            "Mallol C, et al. AAV-mediated pancreatic overexpression of  Igf1 counteracts progression to autoimmune diabetes in mice. Mol 2011;2011:594851.2015;23(5):866–874.Metab. 2017;6(7):664–680.",
            "Flores RR, Zhou L, Robbins PD. Expression of  IL-2 in β cells by AAV8 gene transfer in pre-diabetic NOD mice prevents diabe-tes through activation of  FoxP3-positive regulatory T cells. Gene Ther. 2014;21(8):715–722.",
            "Chen M, et al. Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. Hum Gene Ther Methods. 2017;28(1):49–59.",
            "Lisowski L, et al. Selection and evaluation of  clinically relevant AAV variants in a xenograft liver model. Nature.",
            "Song Z, et al. Strong Alpha Cell Preference of  the AAV Strains That Best Transduce Human Pancreatic Islets In Vitro. Molecular 2001;50(3):515–520.Acad Sci USA. 2001;98(24):13913–13918.ciated viruses. J Virol. 2008;82(12):5887–5911.2014;506(7488):382–386.Therapy. 2017;25(5S1):47.Natl Acad Sci USA. 1994;91(22):10747–10751.antigen. Vaccine. 2006;24(3):335–344.",
            "Gray SJ, et al. Directed evolution of  a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-",
            "Li W, et al. Engineering and selection of  shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. brain barrier (BBB). Mol Ther. 2010;18(3):570–578.Mol Ther. 2008;16(7):1252–1260.insight.jci.org      https://doi.org/10.1172/jci.insight.1316101 7TECHNICAL ADVANCE\fMethods. Methods Mol Biol. 2019;1950:333–360.directed evolution. Mol Ther. 2015;23(4):675–682.Capsids. Hum Gene Ther. 2019;30(1):21–35.2011;85(23):12686–12697.Acad Sci USA. 2010;107(22):10220–10225.Methods Clin Dev. 2018;10:144–155.Seroreactivity. Mol Ther. 2018;26(1):289–303.serotypes. Gene Ther. 2017;24(6):361–369.Acad Sci USA. 2009;106(10):3946–3951.2011;709:127–139.",
            "Paulk NK, et al. Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral",
            "Tervo DG, et al. A Designer AAV Variant Permits Efficient Retrograde Access to Projection Neurons. Neuron. 2016;92(2):372–382. 50. Yang L, et al. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl",
            "Yang L, Li J, Xiao X. Directed evolution of  adeno-associated virus (AAV) as vector for muscle gene therapy. Methods Mol Biol.",
            "Lerch TF, Chapman MS. Identification of  the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology. 2019;8(1):194–206.Cell Biol. 2019;21(2):263–274.2012;423(1):6–13.",
            "Palaschak B, Herzog RW, Markusic DM. AAV-Mediated Gene Delivery to the Liver: Overview of  Current Technologies and",
            "Nonnenmacher M, van Bakel H, Hajjar RJ, Weber T. High capsid-genome correlation facilitates creation of  AAV libraries for",
            "Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl",
            "Earley LF, et al. Adeno-associated Virus (AAV) Assembly-Activating Protein Is Not an Essential Requirement for Capsid Assembly of  AAV Serotypes 4, 5, and 11. J Virol. 2017;91(3):e01980-16.",
            "Hibberts F, Barnes E. The use of  endoscopic retrograde cholangio pancreatography. Nurs Times. 2003;99(20):26–27. 68. Quirin KA, et al. Safety and Efficacy of  AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer",
            "Deverman BE, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol.",
            "Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of  AAV-PHP.B Are Limited to Mice. Mol Ther Methods Clin Dev. 2018;8:8–20.2016;34(2):204–209.C57BL/6J Mice. Mol Ther. 2018;26(3):664–668.",
            "Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018;9(9):273–293. 73. George L, et al. Spk-8011: preliminary results from a phase 1/2 dose escalation trial of  an investigational AAV-mediated gene therapy for hemophilia A. Blood. 2017;130:604.",
            "Wang L, et al. Comparative Study of  Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids.",
            "Kienle E, et al. Engineering and evolution of  synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuf-",
            "Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of  receptor-binding in adeno-associated virus serotype 6 Mol Ther. 2015;23(12):1877–1887.fling. J Vis Exp. 2012;(62):3819.(AAV-6). Virology. 2011;420(1):10–19."
        ],
        "AAV_terms": [
            "AAV",
            "AAV-KP1",
            "AAV-mediated",
            "AAV8",
            "AAV8-based",
            "AAV6",
            "AAV5",
            "AAV2",
            "AAV-DJ",
            "AAV-LK03",
            "AAV3B",
            "AAVs",
            "AAV-expressing",
            "AAV1",
            "AAV8-derived",
            "AAV-FLuc",
            "AAV-KP2",
            "AAV-KP3",
            "AAV-",
            "AAV-KP",
            "AAV-Td",
            "AAV-PHP",
            "AAV4",
            "AAV9hu14",
            "AAV12",
            "AAV-bovine",
            "AAV-avian",
            "AAV-CAG-GFP",
            "AAV-CAG-FLuc",
            "AAV-CAG-tdTomato",
            "AAV-3B",
            "AAV-Mediated",
            "AAV-6"
        ],
        "PMCID": "PMC6948855",
        "PMID": "31723052"
    },
    {
        "Publi_ID": "Pub_000004",
        "Year": 2020,
        "Authors": [
            "Kathleen Börner",
            "Eike Kienle",
            "Lin-Ya Huang",
            "Jonas Weinmann",
            "Anna Sacher",
            "Philipp Bayer",
            "Christian Stüllein",
            "Julia Fakhiri",
            "Laura Zimmermann",
            "Adrian Westhaus",
            "Jürgen Beneke",
            "Nina Beil",
            "Ellen Wiedtke",
            "Carolin Schmelas",
            "Dominik Miltner",
            "Alexander Rau",
            "Holger Erfle",
            "Hans-Georg Kräusslich",
            "Martin Müller",
            "Mavis Agbandje-McKenna",
            "Dirk Grimm"
        ],
        "Title": "Pre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening.",
        "Journal": "Mol Ther",
        "DOI": "10.1016/j.ymthe.2020.02.009",
        "Keywords": [],
        "Pages": 17,
        "Abstract": "Display of short peptides on the surface of adeno-associated viruses (AAVs) is a powerful technology for the generation of gene therapy vectors with altered cell specificities and/or transduction efficiencies. Following its extensive prior use in the best characterized AAV serotype 2 (AAV2), recent reports also indicate the potential of other AAV isolates as scaffolds for peptide display. In this study, we systematically explored the respective capacities of 13 different AAV capsid variants to tolerate 27 peptides inserted on the surface followed by production of reporter-encoding vectors. Single-round screening in pre-arrayed 96-well plates permitted rapid and simple identification of superior vectors in >90 cell types, including T cells and primary cells. Notably, vector performance depended not only on the combination of capsid, peptide, and cell type, but also on the position of the inserted peptide and the nature of flanking residues. For optimal data availability and accessibility, all results were assembled in a searchable online database offering multiple output styles. Finally, we established a reverse-transduction pipeline based on vector pre-spotting in 96- or 384-well plates that facilitates high-throughput library panning. Our comprehensive illustration of the vast potential of alternative AAV capsids for peptide display should accelerate their in vivo screening and application as unique gene therapy vectors.",
        "Total_word_count": 9884,
        "AAV_count": 347,
        "Frequency": 0.035107244,
        "Linked_references": [
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, millions of viruses, and one goal—tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Asokan, A., Schaffer, D.V., and Samulski, R.J. (2012). The AAV vector toolkit: poised at the clinical crossroads. Mol. Ther. 20, 699–708.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam, M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Hordeaux, J., Yuan, Y., Clark, P.M., Wang, Q., Martino, R.A., Sims, J.J., Bell, P., Raymond, A., Stanford, W.L., and Wilson, J.M. (2019). The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912–921.",
            "Matsuzaki, Y., Tanaka, M., Hakoda, S., Masuda, T., Miyata, R., Konno, A., and Hirai, H. (2019). Neurotropic properties of AAV-PHP.B are shared among diverse inbred strains of mice. Mol. Ther. 27, 700–704.",
            "Vandenberghe, L.H. (2019). AAV engineering identifies a species barrier that high- lights a portal to the brain. Mol. Ther. 27, 901–903.",
            "Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modification of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Tan, F., Chu, C., Qi, J., Li, W., You, D., Li, K., Chen, X., Zhao, W., Cheng, C., Liu, X., et al. (2019). AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat. Commun. 10, 3733.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)- based random peptide display library system: infection-defective AAV1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. Gene Med. 8, 1307–1319.",
            "Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Lau, C.H., Ho, J.W., Lo, P.K., and Tin, C. (2019). Targeted transgene activation in the brain tissue by systemic delivery of engineered AAV1 expressing CRISPRa. Mol. Ther. Nucleic Acids 16, 637–649.",
            "Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018). AAVvector-mediated in vivo re- programming into pluripotency. Nat. Commun. 9, 2651."
        ],
        "AAV_terms": [
            "AAV",
            "AAVs",
            "AAV2",
            "AAV-cell",
            "AAV-PHP",
            "AAV9",
            "AAV1",
            "AAV5",
            "AAV6",
            "AAV8",
            "AAV-DJ24",
            "AAV-",
            "AAV-DJ",
            "AAV3",
            "AAVrh",
            "AAVpo",
            "AAV12",
            "AAV4",
            "AAV7",
            "AAV1P4",
            "AAV1P5",
            "AAV9A2",
            "AAV9P1",
            "AAVDJ-NLVRAPS",
            "AAV7A2",
            "AAV7A6",
            "AAV7P2",
            "AAVDJ-NXXR",
            "AAV415",
            "AAV-peptide",
            "AAV-DJP2",
            "AAV-ie",
            "AAV/CRISPR",
            "AAVvector-mediated"
        ],
        "PMCID": "PMC7132618",
        "PMID": "32105604"
    },
    {
        "Publi_ID": "Pub_000005",
        "Year": 2019,
        "Authors": [
            "Hildegard Büning",
            "Arun Srivastava"
        ],
        "Title": "Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors.",
        "Journal": "Mol Ther Methods Clin Dev",
        "DOI": "10.1016/j.omtm.2019.01.008",
        "Keywords": [],
        "Pages": 18,
        "Abstract": "In the past decade, recombinant vectors based on a non-pathogenic parvovirus, the adeno-associated virus (AAV), have taken center stage as a gene delivery vehicle for the potential gene therapy for a number of human diseases. To date, the safety of AAV vectors in 176 phase I, II, and III clinical trials and their efficacy in at least eight human diseases are now firmly documented. Despite these remarkable achievements, it has also become abundantly clear that the full potential of first generation AAV vectors composed of naturally occurring capsids is not likely to be realized, since the wild-type AAV did not evolve for the purpose of therapeutic gene delivery. In this article, we provide a brief historical account of the progress that has been made in the development of capsid-modified",
        "Total_word_count": 11592,
        "AAV_count": 493,
        "Frequency": 0.0425293306,
        "Linked_references": [
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427.",
            "Weinmann, J., and Grimm, D. (2017). Next-generation AAV vectors for clinical use: an ever-accelerating race. Virus Genes 53, 707–713.",
            "Samulski, R.J., and Muzyczka, N. (2014). AAV-mediated gene therapy for research and therapeutic purposes. Annu. Rev. Virol. 1, 427–451.",
            "Muzyczka, N., and Berns, K.I. (2015). AAV’s golden jubilee. Mol. Ther. 23, 807–808.",
            "Grimm, D., and Zolotukhin, S. (2015). E pluribus unum: 50 years of research, mil- lions of viruses, and one goal: Tailored acceleration of AAV evolution. Mol. Ther. 23, 1819–1831.",
            "Berns, K.I., and Muzyczka, N. (2017). AAV: an overview of unanswered questions. Hum. Gene Ther. 28, 308–313.",
            "Chiorini, J.A., Yang, L., Liu, Y., Safer, B., and Kotin, R.M. (1997). Cloning of adeno- associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823–6833.",
            "Rutledge, E.A., Halbert, C.L., and Russell, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 72, 309–319.",
            "Schmidt, M., Govindasamy, L., Afione, S., Kaludov, N., Agbandje-McKenna, M., and Chiorini, J.A. (2008). Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 82, 8911–8916.",
            "Schmidt, M., Voutetakis, A., Afione, S., Zheng, C., Mandikian, D., and Chiorini, J.A. (2008). Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 82, 1399–1406.",
            "Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G.F., Wong, W.Y., and Pasi, K.J. (2017). AAV5-factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530.",
            "Byrne, P.I., Collins, S., Mah, C.C., Smith, B., Conlon, T., Martin, S.D., Corti, M., Cleaver, B., Islam, S., and Lawson, L.A. (2014). Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV- GAA) gene vector in patients with Pompe disease. Hum. Gene Ther. Clin. Dev. 25, 134–163.",
            "Cao, M., You, H., and Hermonat, P.L. (2014). The X gene of adeno-associated virus 2 (AAV2) is involved in viral DNA replication. PLoS ONE 9, e104596.",
            "Sonntag, F., Schmidt, K., and Kleinschmidt, J.A. (2010). A viral assembly factor pro- motes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. USA 107, 10220–10225.",
            "Halder, S., Van Vliet, K., Smith, J.K., Duong, T.T., McKenna, R., Wilson, J.M., and Agbandje-McKenna, M. (2015). Structure of neurotropic adeno-associated virus AAVrh.8. J. Struct. Biol. 192, 21–36.",
            "Tseng, Y.S., and Agbandje-McKenna, M. (2014). Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vec- tors. Front. Immunol. 5, 9.",
            "Rabinowitz, J.E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., and Samulski, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791–801.",
            "Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., and Chapman, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 10405–10410.",
            "Uhrig, S., Coutelle, O., Wiehe, T., Perabo, L., Hallek, M., and Büning, H. (2012). Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther. 19, 210–218.",
            "Büning, H., Huber, A., Zhang, L., Meumann, N., and Hacker, U. (2015). Engineering the AAV capsid to optimize vector-host-interactions. Curr. Opin. Pharmacol. 24, 94–104.",
            "Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., and Muzyczka, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635–8647.",
            "Wang, L.R., McLaughlin, T., Cossette, T., Tang, Q., Foust, K., Campbell-Thompson, M., Martino, A., Cruz, P., Loiler, S., Mueller, C., and Flotte, T.R. (2009). Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery. Mol. Ther. 17, 81–87.",
            "Shi, W., Arnold, G.S., and Bartlett, J.S. (2001). Insertional mutagenesis of the adeno- associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors tar- geted to alternative cell-surface receptors. Hum. Gene Ther. 12, 1697–1711.",
            "Arnold, G.S., Sasser, A.K., Stachler, M.D., and Bartlett, J.S. (2006). Metabolic bio- tinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14, 97–106.",
            "Asokan, A., Johnson, J.S., Li, C., and Samulski, R.J. (2008). Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Ther. 15, 1618–1622.",
            "Choudhury, S.R., Harris, A.F., Cabral, D.J., Keeler, A.M., Sapp, E., Ferreira, J.S., Gray-Edwards, H.L., Johnson, J.A., Johnson, A.K., Su, Q., et al. (2016). Widespread central nervous system gene transfer and silencing after systemic deliv- ery of novel AAV-AS vector. Mol. Ther. 24, 726–735.",
            "Hartmann, J., Münch, R.C., Freiling, R.T., Schneider, I.C., Dreier, B., Samukange, W., Koch, J., Seeger, M.A., Plückthun, A., and Buchholz, C.J. (2018). A library-based screening strategy for the identification of DARPins as ligands for receptor-targeted AAV and lentiviral vectors. Mol. Ther. Methods Clin. Dev. 10, 128–143.",
            "Hagen, S., Baumann, T., Wagner, H.J., Morath, V., Kaufmann, B., Fischer, A., Bergmann, S., Schindler, P., Arndt, K.M., and Müller, K.M. (2014). Modular adeno-associated virus (rAAV) vectors used for cellular virus-directed enzyme pro- drug therapy. Sci. Rep. 4, 3759.",
            "Adachi, K., and Nakai, H. (2010). A new recombinant adeno-associated virus (AAV)-based random peptide display library system: Infection-defective Aav1.9-3 as a novel detargeted platform for vector evolution. Gene Ther. Regul. 5, 31–55.",
            "Deverman, B.E., Pravdo, P.L., Simpson, B.P., Kumar, S.R., Chan, K.Y., Banerjee, A., Wu, W.L., Yang, B., Huber, N., Pasca, S.P., and Gradinaru, V. (2016). Cre-depen- dent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204–209.",
            "Varadi, K., Michelfelder, S., Korff, T., Hecker, M., Trepel, M., Katus, H.A., Kleinschmidt, J.A., and Müller, O.J. (2012). Novel random peptide libraries dis- played on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 19, 800–809.",
            "Naumer, M., Ying, Y., Michelfelder, S., Reuter, A., Trepel, M., Müller, O.J., and Kleinschmidt, J.A. (2012). Development and validation of novel AAV2 random li- braries displaying peptides of diverse lengths and at diverse capsid positions. Hum. Gene Ther. 23, 492–507.",
            "Sallach, J., Di Pasquale, G., Larcher, F., Niehoff, N., Rübsam,M., Huber, A., Chiorini, J., Almarza, D., Eming, S.A., Ulus, H., et al. (2014). Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy. Mol. Ther. 22, 929–939.",
            "Zhong, L., Li, B., Jayandharan, G., Mah, C.S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R.W., Weigel-Van Aken, K.A., Hobbs, J.A., Zolotukhin, S., et al. (2008). Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracel- lular trafficking and transgene expression. Virology 381, 194–202.",
            "Markusic, D.M., Herzog, R.W., Aslanidi, G.V., Hoffman, B.E., Li, B., Li, M., Jayandharan, G.R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010). High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol. Ther. 18, 2048–2056.",
            "Martino, A.T., Basner-Tschakarjan, E., Markusic, D.M., Finn, J.D., Hinderer, C., Zhou, S., Ostrov, D.A., Srivastava, A., Ertl, H.C., Terhorst, C., et al. (2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 121, 2224–2233.",
            "Aslanidi, G.V., Rivers, A.E., Ortiz, L., Song, L., Ling, C., Govindasamy, L., Van Vliet, K., Tan, M., Agbandje-McKenna, M., and Srivastava, A. (2013). Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS ONE 8, e59142.",
            "0. Aslanidi, G.V., Rivers, A.E., Ortiz, L., Govindasamy, L., Ling, C., Jayandharan, G.R., Zolotukhin, S., Agbandje-McKenna, M., and Srivastava, A. (2012). High-efficiency transduction of humanmonocyte-derived dendritic cells by capsid-modified recom- binant AAV2 vectors. Vaccine 30, 3908–3917.",
            "1. Li, B., Ma, W., Ling, C., Van Vliet, K., Huang, L.Y., Agbandje-McKenna, M., Srivastava, A., and Aslanidi, G.V. (2015). Site-directed mutagenesis of surface- exposed lysine residues leads to improved transduction by AAV2, but not AAV8, vectors in murine hepatocytes in vivo. Hum. Gene Ther. Methods 26, 211–220.",
            "2. Glushakova, L.G., Lisankie, M.J., Eruslanov, E.B., Ojano-Dirain, C., Zolotukhin, I., Liu, C., Srivastava, A., and Stacpoole, P.W. (2009). AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol. Genet. Metab. 98, 289–299.",
            "4. Ling, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014). Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. Hum. Gene Ther. 25, 1023–1034.",
            "5. Vercauteren, K., Hoffman, B.E., Zolotukhin, I., Keeler, G.D., Xiao, J.W., Basner- Tschakarjan, E., High, K.A., Ertl, H.C., Rice, C.M., Srivastava, A., et al. (2016). Superior In vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol. Ther. 24, 1042–1049.",
            "6. Li, S., Ling, C., Zhong, L., Li, M., Su, Q., He, R., Tang, Q., Greiner, D.L., Shultz, L.D., Brehm, M.A., et al. (2015). Efficient and targeted transduction of nonhuman pri- mate liver with systemically delivered optimized AAV3B vectors. Mol. Ther. 23, 1867–1876.",
            "7. Ling, C., Bhukhai, K., Yin, Z., Tan, M., Yoder, M.C., Leboulch, P., Payen, E., and Srivastava, A. (2016). High-efficiency transduction of primary human hematopoiet- ic stem/progenitor cells by AAV6 vectors: strategies for overcoming donor-variation and implications in genome editing. Sci. Rep. 6, 35495.",
            "8. Song, L., Kauss, M.A., Kopin, E., Chandra, M., Ul-Hasan, T., Miller, E., Jayandharan, G.R., Rivers, A.E., Aslanidi, G.V., Ling, C., et al. (2013). Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors",
            "9. Wang, J., Exline, C.M., DeClercq, J.J., Llewellyn, G.N., Hayward, S.B., Li, P.W., Shivak, D.A., Surosky, R.T., Gregory, P.D., Holmes, M.C., and Cannon, P.M. (2015). Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat. Biotechnol. 33, 1256–1263.",
            "0. Sather, B.D., Romano Ibarra, G.S., Sommer, K., Curinga, G., Hale, M., Khan, I.F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015). Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci. Transl. Med. 7, 307ra156.",
            "7. Nicklin, S.A., Buening, H., Dishart, K.L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A.J., Ali, R.R., Hallek, M., and Baker, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174–181.",
            "2. Yu, C.Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., and Xiao, X. (2009). A muscle- targeting peptide displayed on AAV2 improves muscle tropism on systemic deliv- ery. Gene Ther. 16, 953–962.",
            "5. Geoghegan, J.C., Keiser, N.W., Okulist, A., Martins, I., Wilson, M.S., and Davidson, B.L. (2014). Chondroitin sulfate is the primary receptor for a peptide-modified AAV that targets brain vascular endothelium in vivo. Mol. Ther. Nucleic Acids 3, e202.",
            "9. Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Bentley-Lukschal, A., Stremnitzer, C., Roth-Walter, F., Weghofer, M., Ritter, M., Pino Tossi, K., et al. (2016). Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. OncoImmunology 5, e1171446.",
            "0. Shi, W., and Bartlett, J.S. (2003). RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism. Mol. Ther. 7, 515–525.",
            "1. Waterkamp, D.A., Müller, O.J., Ying, Y., Trepel, M., and Kleinschmidt, J.A. (2006). Isolation of targeted AAV2 vectors from novel virus display libraries. J. GeneMed. 8, 1307–1319.",
            "3. Stiefelhagen, M., Sellner, L., Kleinschmidt, J.A., Jauch, A., Laufs, S., Wenz, F., Zeller, W.J., Fruehauf, S., and Veldwijk,M.R. (2008). Application of a haematopoetic progen- itor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line. Genet. Vaccines Ther. 6, 12.",
            "4. Sellner, L., Stiefelhagen, M., Kleinschmidt, J.A., Laufs, S., Wenz, F., Fruehauf, S., Zeller, W.J., and Veldwijk, M.R. (2008). Generation of efficient human blood pro- genitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Exp. Hematol. 36, 957–964.",
            "9. Shi, X., Fang, G., Shi, W., and Bartlett, J.S. (2006). Insertional mutagenesis at posi- tions 520 and 584 of adeno-associated virus type 2 (AAV2) capsid gene and gener- ation of AAV2 vectors with eliminated heparin- binding ability and introduced novel tropism. Hum. Gene Ther. 17, 353–361.",
            "0. Konkalmatt, P.R., Deng, D., Thomas, S., Wu, M.T., Logsdon, C.D., French, B.A., and Kelly, K.A. (2013). Plectin-1 targeted AAV vector for the molecular imaging of pancreatic cancer. Front. Oncol. 3, 84.",
            "1. Stachler, M.D., Chen, I., Ting, A.Y., and Bartlett, J.S. (2008). Site-specific modifica- tion of AAV vector particles with biophysical probes and targeting ligands using biotin ligase. Mol. Ther. 16, 1467–1473.",
            "2. Stachler, M.D., and Bartlett, J.S. (2006). Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13, 926–931.",
            "3. Davis, A.S., Federici, T., Ray, W.C., Boulis, N.M., OʼConnor, D., Clark, K.R., and Bartlett, J.S. (2015). Rational design and engineering of a modified adeno-associated virus (AAV1)-based vector system for enhanced retrograde gene delivery. Neurosurgery 76, 216–225, discussion 225.",
            "4. Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A.P., Sahel, J.A., and Dalkara, D. (2016). Insight into the mechanisms of enhanced retinal transduction by the engineered AAV2 capsid variant -7m8. Biotechnol. Bioeng. 113, 2712–2724.",
            "5. Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., and Aslanidi, G. (2016). Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther. 23, 18–25.",
            "6. Michelfelder, S., Varadi, K., Raupp, C., Hunger, A., Körbelin, J., Pahrmann, C., Schrepfer, S., Müller, O.J., Kleinschmidt, J.A., and Trepel, M. (2011). Peptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivo. PLoS ONE 6, e23101.",
            "7. Kunze, C., Börner, K., Kienle, E., Orschmann, T., Rusha, E., Schneider, M., Radivojkov-Blagojevic, M., Drukker, M., Desbordes, S., Grimm, D., and Brack- Werner, R. (2018). Synthetic AAV/CRISPR vectors for blocking HIV-1 expression in persistently infected astrocytes. Glia 66, 413–427."
        ],
        "AAV_terms": [
            "AAV",
            "AAV2",
            "AAV1",
            "AAV8",
            "AAV5",
            "AAV9",
            "AAV1-LPL",
            "AAV3",
            "AAV6",
            "AAV10",
            "AAVS1",
            "AAV2-speciﬁc",
            "AAV4",
            "AAV-588NGR",
            "AAV-I-587",
            "AAV-MO7A",
            "AAV-MO7T",
            "AAV-MecA",
            "AAV-MecB",
            "AAV-C4",
            "AAV-D10",
            "AAV-SIG",
            "AAV-MTP",
            "AAV-QPE",
            "AAV-VNT",
            "AAV-CNH",
            "AAV-CAP",
            "AAV-EYH",
            "AAV587MTP",
            "AAV-r3",
            "AAV2-LSS",
            "AAV2-PFG",
            "AAV2-PPS",
            "AAV2-TLH",
            "AAV2-GMN",
            "AAV2-7m8",
            "AAV-Kera1",
            "AAV-Kera2",
            "AAV-Kera3",
            "AAV-588Myc",
            "AAV2-Z34C",
            "AAV-VTAGRAP",
            "AAV-APVTRPA",
            "AAV-DLSNLTR",
            "AAV-NQVGSWS",
            "AAV-EARVRPP",
            "AAV-NSVSLYT",
            "AAV-LS1",
            "AAV-LS2",
            "AAV-LS3",
            "AAV-LS4",
            "AAV-RGDLGLS",
            "AAV-RGDMSRE",
            "AAV-ESGLSQS",
            "AAV-EYRDSSG",
            "AAV-DLGSARA",
            "AAV-NDVRSAN",
            "AAV-GPQGKNS",
            "AAV-NSSRDLG",
            "AAV-NDVRAVS",
            "AAV-PRSTSDP",
            "AAV-DIIRA",
            "AAV-SYENV",
            "AAV-PENSV",
            "AAV-LSLAS",
            "AAV2-5-mer",
            "AAV2-12-mer",
            "AAV-NDVWN",
            "AAV2-19-mer",
            "AAV-NRTYS",
            "AAV2-ESGHGYF",
            "AAV-GQHPRPG",
            "AAV-PSVSPRP",
            "AAV2-VNSTRLP",
            "AAV-GQHPR",
            "AAV-LSPVR",
            "AAV-MSSDP",
            "AAV-GARPS",
            "AAV-GNEVL",
            "AAV2-7-mer",
            "AAV-KMRPG",
            "AAV588MTP",
            "AAV-MNVRGDL",
            "AAV-ENVRGDL",
            "AAV2-453-peptide",
            "AAV-DIV-NGR",
            "AAV-PTP",
            "AAV1-RGD",
            "AAV6-RGD-Y705-731F",
            "AAV6-RGD-Y705",
            "AAV8-SEGLKNL",
            "AAV-RGDLRVS",
            "AAV5-7m8",
            "AAV6-RGD",
            "AAV2/8-BP2",
            "AAV8-PRSTSDP",
            "AAV8-ESGLSOS",
            "AAV8-VNSTRLP",
            "AAV8-ASSLNIA",
            "AAV8-PSVSPRP",
            "AAV8-GQHPRPG",
            "AAV8-7m8",
            "AAV-SLRSPPS",
            "AAV9-NDVRAVS",
            "AAV9-PRSTSDP",
            "AAV9-ESGLSOS",
            "AAV-PHP",
            "AAV9-7m8",
            "AAV9P1",
            "AAV2-based",
            "AAV6107",
            "AAV-mediated",
            "AAV(VR-942)",
            "AAV12",
            "AAV1-LPLS447X",
            "AAV5-factor",
            "AAVrh",
            "AAV-2",
            "AAV-AS",
            "AAV3-mediated",
            "AAV3B",
            "AAV2-mediated",
            "AAV-mimotope",
            "AAV/CRISPR"
        ],
        "PMCID": "PMC6378346",
        "PMID": "30815511"
    },
    {
        "Publi_ID": "Pub_000006",
        "Year": 2018,
        "Authors": [
            "Esther J Lee",
            "Caitlin M Guenther",
            "Junghae Suh"
        ],
        "Title": "Adeno-Associated Virus (AAV) Vectors: Rational Design Strategies for Capsid Engineering.",
        "Journal": "Curr Opin Biomed Eng",
        "DOI": "10.1016/j.cobme.2018.09.004",
        "Keywords": [
            "AAV",
            "Adeno-associated virus",
            "gene delivery",
            "gene therapy",
            "rational design",
            "review",
            "synthetic virology",
            "viral vector"
        ],
        "Pages": 11,
        "Abstract": "Adeno-associated virus (AAV) consists of a simple genome, infects mammalian cells, displays nonpathogenicity in humans, and spans an array of serotypes and variants bearing distinct tissue tropisms. These attributes lend AAV tremendous promise as a gene delivery vector, further substantiated by its extensive testing in human clinical trials. Rational design approaches to capsid engineering leverage current scientific knowledge of AAV to further modulate, enhance and optimize the performance of the vectors. Capsid modification strategies include amino acid point mutations, peptide domain insertions, and chemical biology approaches. Through such efforts, insights regarding AAV capsid sequence-structure-function relationships can be learned. Developments over the last 5 years in rational design-based capsid engineering approaches will be presented and discussed.",
        "Total_word_count": 3994,
        "AAV_count": 127,
        "Frequency": 0.0317976965,
        "Linked_references": [
            "Earley LF, Powers JM, Adachi K, Baumgart JT, Meyer NL, Xie Q, Chapman MS, Nakai H: Adeno- associated virus (aav) assembly-activating protein is not an essential requirement for capsid  assembly of aav serotypes 4, 5, and 11. Journal of virology (2017) 91(3):e01980–01916. [PubMed:  27852862]",
            "McCarty DM, Young SM Jr, Samulski RJ: Integration of adeno-associated virus (aav) and  recombinant aav vectors. Annu Rev Genet (2004) 38(819–845. [PubMed: 15568995]",
            "Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS: The atomic structure of  adeno-associated virus (aav-2), a vector for human gene therapy.Proceedings of the National  Academy of Sciences (2002) 99(16):10405–10410.",
            "Agbandje-McKenna M, Kleinschmidt J: Aav capsid structure and cell interactions In: Adeno- associated virus. Springer, (2012):47–92.",
            "Asokan A, Schaffer DV, Samulski RJ: The aav vector toolkit: Poised at the clinical crossroads.  Molecular Therapy (2012) 20(4):699–708. [PubMed: 22273577]",
            "Pillay S, Zou W, Cheng F, Puschnik AS, Meyer NL, Ganaie SS, Deng X, Wosen JE, Davulcu O,  Yan Z, Engelhardt JF et al.: Aav serotypes have distinctive interactions with domains of the  cellular receptor aavr. Journal of virology (2017).",
            "Dudek AM, Pillay S, Puschnik AS, Nagamine CM, Cheng F, Qiu J, Carette JE, Vandenberghe LH:  An alternate route for adeno-associated virus entry independent of aavr. Journal of virology (2018)  JVI–02213.",
            "Calcedo R, Wilson JM: Humoral immune response to aav. Frontiers in immunology (2013) 4(341.  [PubMed: 24151496]",
            "Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, Shah R, Arruda VR,  Mingozzi F, Wright JF: Assessing the potential for aav vector genotoxicity in a murine model.  Blood (2011) 117(12):3311–3319. [PubMed: 21106988]",
            "Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R:  Several raav vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes",
            "Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA: Factor ix  expression in skeletal muscle of a severe hemophilia b patient 10 years after aavmediated gene  transfer. Blood (2012) 119(13):3038–3041. [PubMed: 22271447]",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Kanaan NM, Sellnow RC, Boye SL, Coberly B, Bennett A, Agbandje-McKenna M, Sortwell CE,  Hauswirth WW, Boye SE, Manfredsson FP: Rationally engineered aav capsids improve  transduction and volumetric spread in the cns. Molecular Therapy-Nucleic Acids (2017) 8(184– 197.",
            "Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q: A rationally  engineered capsid variant of aav9 for systemic cns-directed and peripheral tissue-detargeted gene  delivery in neonates. Molecular Therapy-Methods & Clinical Development (2018) 9(234–246.  [PubMed: 29766031]",
            "Bennett AD, Wong K, Lewis J, Tseng Y-S, Smith JK, Chipman P, McKenna R, Samulski RJ,  Kleinschmidt J, Agbandje-McKenna M: Aav6 k531 serves a dual function in selective receptor  and antibody adk6 recognition. Virology (2018) 518(369–376.",
            "Albright BH, Storey CM, Murlidharan G, Rivera RMC, Berry GE, Madigan VJ, Asokan A:  Mapping the structural determinants required for aavrh. 10 transport across the blood-brain  barrier. Molecular Therapy (2017).",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q: A rationally  engineered capsid variant of aav9 for systemic cns-directed and peripheral tissue-detargeted gene  delivery in neonates. Molecular Therapy-Methods & Clinical Development (2018) 9(234–246.  [PubMed: 29766031]",
            "Earley LF, Powers JM, Adachi K, Baumgart JT, Meyer NL, Xie Q, Chapman MS, Nakai H: Adeno- associated virus (aav) assembly-activating protein is not an essential requirement for capsid  assembly of aav serotypes 4, 5, and 11. Journal of virology (2017) 91(3):e01980–01916. [PubMed:  27852862]",
            "McCarty DM, Young SM Jr, Samulski RJ: Integration of adeno-associated virus (aav) and  recombinant aav vectors. Annu Rev Genet (2004) 38(819–845. [PubMed: 15568995]",
            "Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS: The atomic structure of  adeno-associated virus (aav-2), a vector for human gene therapy.Proceedings of the National  Academy of Sciences (2002) 99(16):10405–10410.",
            "Agbandje-McKenna M, Kleinschmidt J: Aav capsid structure and cell interactions In: Adeno- associated virus. Springer, (2012):47–92.",
            "Asokan A, Schaffer DV, Samulski RJ: The aav vector toolkit: Poised at the clinical crossroads.  Molecular Therapy (2012) 20(4):699–708. [PubMed: 22273577]",
            "Pillay S, Zou W, Cheng F, Puschnik AS, Meyer NL, Ganaie SS, Deng X, Wosen JE, Davulcu O,  Yan Z, Engelhardt JF et al.: Aav serotypes have distinctive interactions with domains of the  cellular receptor aavr. Journal of virology (2017).",
            "Dudek AM, Pillay S, Puschnik AS, Nagamine CM, Cheng F, Qiu J, Carette JE, Vandenberghe LH:  An alternate route for adeno-associated virus entry independent of aavr. Journal of virology (2018)  JVI–02213.",
            "Calcedo R, Wilson JM: Humoral immune response to aav. Frontiers in immunology (2013) 4(341.  [PubMed: 24151496]",
            "Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, Shah R, Arruda VR,  Mingozzi F, Wright JF: Assessing the potential for aav vector genotoxicity in a murine model.  Blood (2011) 117(12):3311–3319. [PubMed: 21106988]",
            "Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R:  Several raav vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes",
            "Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA: Factor ix  expression in skeletal muscle of a severe hemophilia b patient 10 years after aavmediated gene  transfer. Blood (2012) 119(13):3038–3041. [PubMed: 22271447]",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Kanaan NM, Sellnow RC, Boye SL, Coberly B, Bennett A, Agbandje-McKenna M, Sortwell CE,  Hauswirth WW, Boye SE, Manfredsson FP: Rationally engineered aav capsids improve  transduction and volumetric spread in the cns. Molecular Therapy-Nucleic Acids (2017) 8(184– 197.",
            "Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q: A rationally  engineered capsid variant of aav9 for systemic cns-directed and peripheral tissue-detargeted gene  delivery in neonates. Molecular Therapy-Methods & Clinical Development (2018) 9(234–246.  [PubMed: 29766031]",
            "Bennett AD, Wong K, Lewis J, Tseng Y-S, Smith JK, Chipman P, McKenna R, Samulski RJ,  Kleinschmidt J, Agbandje-McKenna M: Aav6 k531 serves a dual function in selective receptor  and antibody adk6 recognition. Virology (2018) 518(369–376.",
            "Albright BH, Storey CM, Murlidharan G, Rivera RMC, Berry GE, Madigan VJ, Asokan A:  Mapping the structural determinants required for aavrh. 10 transport across the blood-brain  barrier. Molecular Therapy (2017).",
            "Earley LF, Powers JM, Adachi K, Baumgart JT, Meyer NL, Xie Q, Chapman MS, Nakai H: Adeno- associated virus (aav) assembly-activating protein is not an essential requirement for capsid  assembly of aav serotypes 4, 5, and 11. Journal of virology (2017) 91(3):e01980–01916. [PubMed:  27852862]",
            "McCarty DM, Young SM Jr, Samulski RJ: Integration of adeno-associated virus (aav) and  recombinant aav vectors. Annu Rev Genet (2004) 38(819–845. [PubMed: 15568995]",
            "Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS: The atomic structure of  adeno-associated virus (aav-2), a vector for human gene therapy.Proceedings of the National  Academy of Sciences (2002) 99(16):10405–10410.",
            "Agbandje-McKenna M, Kleinschmidt J: Aav capsid structure and cell interactions In: Adeno- associated virus. Springer, (2012):47–92.",
            "Asokan A, Schaffer DV, Samulski RJ: The aav vector toolkit: Poised at the clinical crossroads.  Molecular Therapy (2012) 20(4):699–708. [PubMed: 22273577]",
            "Pillay S, Zou W, Cheng F, Puschnik AS, Meyer NL, Ganaie SS, Deng X, Wosen JE, Davulcu O,  Yan Z, Engelhardt JF et al.: Aav serotypes have distinctive interactions with domains of the  cellular receptor aavr. Journal of virology (2017).",
            "Dudek AM, Pillay S, Puschnik AS, Nagamine CM, Cheng F, Qiu J, Carette JE, Vandenberghe LH:  An alternate route for adeno-associated virus entry independent of aavr. Journal of virology (2018)  JVI–02213.",
            "Calcedo R, Wilson JM: Humoral immune response to aav. Frontiers in immunology (2013) 4(341.  [PubMed: 24151496]",
            "Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, Shah R, Arruda VR,  Mingozzi F, Wright JF: Assessing the potential for aav vector genotoxicity in a murine model.  Blood (2011) 117(12):3311–3319. [PubMed: 21106988]",
            "Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R:  Several raav vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes",
            "Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA: Factor ix  expression in skeletal muscle of a severe hemophilia b patient 10 years after aavmediated gene  transfer. Blood (2012) 119(13):3038–3041. [PubMed: 22271447]",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Kanaan NM, Sellnow RC, Boye SL, Coberly B, Bennett A, Agbandje-McKenna M, Sortwell CE,  Hauswirth WW, Boye SE, Manfredsson FP: Rationally engineered aav capsids improve  transduction and volumetric spread in the cns. Molecular Therapy-Nucleic Acids (2017) 8(184– 197.",
            "Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q: A rationally  engineered capsid variant of aav9 for systemic cns-directed and peripheral tissue-detargeted gene  delivery in neonates. Molecular Therapy-Methods & Clinical Development (2018) 9(234–246.  [PubMed: 29766031]",
            "Bennett AD, Wong K, Lewis J, Tseng Y-S, Smith JK, Chipman P, McKenna R, Samulski RJ,  Kleinschmidt J, Agbandje-McKenna M: Aav6 k531 serves a dual function in selective receptor  and antibody adk6 recognition. Virology (2018) 518(369–376.",
            "Albright BH, Storey CM, Murlidharan G, Rivera RMC, Berry GE, Madigan VJ, Asokan A:  Mapping the structural determinants required for aavrh. 10 transport across the blood-brain  barrier. Molecular Therapy (2017).",
            "Earley LF, Powers JM, Adachi K, Baumgart JT, Meyer NL, Xie Q, Chapman MS, Nakai H: Adeno- associated virus (aav) assembly-activating protein is not an essential requirement for capsid  assembly of aav serotypes 4, 5, and 11. Journal of virology (2017) 91(3):e01980–01916. [PubMed:  27852862]",
            "McCarty DM, Young SM Jr, Samulski RJ: Integration of adeno-associated virus (aav) and  recombinant aav vectors. Annu Rev Genet (2004) 38(819–845. [PubMed: 15568995]",
            "Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS: The atomic structure of  adeno-associated virus (aav-2), a vector for human gene therapy.Proceedings of the National  Academy of Sciences (2002) 99(16):10405–10410.",
            "Agbandje-McKenna M, Kleinschmidt J: Aav capsid structure and cell interactions In: Adeno- associated virus. Springer, (2012):47–92.",
            "Asokan A, Schaffer DV, Samulski RJ: The aav vector toolkit: Poised at the clinical crossroads.  Molecular Therapy (2012) 20(4):699–708. [PubMed: 22273577]",
            "Pillay S, Zou W, Cheng F, Puschnik AS, Meyer NL, Ganaie SS, Deng X, Wosen JE, Davulcu O,  Yan Z, Engelhardt JF et al.: Aav serotypes have distinctive interactions with domains of the  cellular receptor aavr. Journal of virology (2017).",
            "Dudek AM, Pillay S, Puschnik AS, Nagamine CM, Cheng F, Qiu J, Carette JE, Vandenberghe LH:  An alternate route for adeno-associated virus entry independent of aavr. Journal of virology (2018)  JVI–02213.",
            "Calcedo R, Wilson JM: Humoral immune response to aav. Frontiers in immunology (2013) 4(341.  [PubMed: 24151496]",
            "Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, Shah R, Arruda VR,  Mingozzi F, Wright JF: Assessing the potential for aav vector genotoxicity in a murine model.  Blood (2011) 117(12):3311–3319. [PubMed: 21106988]",
            "Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R:  Several raav vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes",
            "Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA: Factor ix  expression in skeletal muscle of a severe hemophilia b patient 10 years after aavmediated gene  transfer. Blood (2012) 119(13):3038–3041. [PubMed: 22271447]",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Kanaan NM, Sellnow RC, Boye SL, Coberly B, Bennett A, Agbandje-McKenna M, Sortwell CE,  Hauswirth WW, Boye SE, Manfredsson FP: Rationally engineered aav capsids improve  transduction and volumetric spread in the cns. Molecular Therapy-Nucleic Acids (2017) 8(184– 197.",
            "Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q: A rationally  engineered capsid variant of aav9 for systemic cns-directed and peripheral tissue-detargeted gene  delivery in neonates. Molecular Therapy-Methods & Clinical Development (2018) 9(234–246.  [PubMed: 29766031]",
            "Bennett AD, Wong K, Lewis J, Tseng Y-S, Smith JK, Chipman P, McKenna R, Samulski RJ,  Kleinschmidt J, Agbandje-McKenna M: Aav6 k531 serves a dual function in selective receptor  and antibody adk6 recognition. Virology (2018) 518(369–376.",
            "Albright BH, Storey CM, Murlidharan G, Rivera RMC, Berry GE, Madigan VJ, Asokan A:  Mapping the structural determinants required for aavrh. 10 transport across the blood-brain  barrier. Molecular Therapy (2017).",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Earley LF, Powers JM, Adachi K, Baumgart JT, Meyer NL, Xie Q, Chapman MS, Nakai H: Adeno- associated virus (aav) assembly-activating protein is not an essential requirement for capsid  assembly of aav serotypes 4, 5, and 11. Journal of virology (2017) 91(3):e01980–01916. [PubMed:  27852862]",
            "McCarty DM, Young SM Jr, Samulski RJ: Integration of adeno-associated virus (aav) and  recombinant aav vectors. Annu Rev Genet (2004) 38(819–845. [PubMed: 15568995]",
            "Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS: The atomic structure of  adeno-associated virus (aav-2), a vector for human gene therapy.Proceedings of the National  Academy of Sciences (2002) 99(16):10405–10410.",
            "Agbandje-McKenna M, Kleinschmidt J: Aav capsid structure and cell interactions In: Adeno- associated virus. Springer, (2012):47–92.",
            "Asokan A, Schaffer DV, Samulski RJ: The aav vector toolkit: Poised at the clinical crossroads.  Molecular Therapy (2012) 20(4):699–708. [PubMed: 22273577]",
            "Pillay S, Zou W, Cheng F, Puschnik AS, Meyer NL, Ganaie SS, Deng X, Wosen JE, Davulcu O,  Yan Z, Engelhardt JF et al.: Aav serotypes have distinctive interactions with domains of the  cellular receptor aavr. Journal of virology (2017).",
            "Dudek AM, Pillay S, Puschnik AS, Nagamine CM, Cheng F, Qiu J, Carette JE, Vandenberghe LH:  An alternate route for adeno-associated virus entry independent of aavr. Journal of virology (2018)  JVI–02213.",
            "Calcedo R, Wilson JM: Humoral immune response to aav. Frontiers in immunology (2013) 4(341.  [PubMed: 24151496]",
            "Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson SE, Shah R, Arruda VR,  Mingozzi F, Wright JF: Assessing the potential for aav vector genotoxicity in a murine model.  Blood (2011) 117(12):3311–3319. [PubMed: 21106988]",
            "Zhang H, Yang B, Mu X, Ahmed SS, Su Q, He R, Wang H, Mueller C, Sena-Esteves M, Brown R:  Several raav vectors efficiently cross the blood–brain barrier and transduce neurons and astrocytes",
            "Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA: Factor ix  expression in skeletal muscle of a severe hemophilia b patient 10 years after aavmediated gene  transfer. Blood (2012) 119(13):3038–3041. [PubMed: 22271447]",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Kanaan NM, Sellnow RC, Boye SL, Coberly B, Bennett A, Agbandje-McKenna M, Sortwell CE,  Hauswirth WW, Boye SE, Manfredsson FP: Rationally engineered aav capsids improve  transduction and volumetric spread in the cns. Molecular Therapy-Nucleic Acids (2017) 8(184– 197.",
            "Wang D, Li S, Gessler DJ, Xie J, Zhong L, Li J, Tran K, Van Vliet K, Ren L, Su Q: A rationally  engineered capsid variant of aav9 for systemic cns-directed and peripheral tissue-detargeted gene  delivery in neonates. Molecular Therapy-Methods & Clinical Development (2018) 9(234–246.  [PubMed: 29766031]",
            "Bennett AD, Wong K, Lewis J, Tseng Y-S, Smith JK, Chipman P, McKenna R, Samulski RJ,  Kleinschmidt J, Agbandje-McKenna M: Aav6 k531 serves a dual function in selective receptor  and antibody adk6 recognition. Virology (2018) 518(369–376.",
            "Albright BH, Storey CM, Murlidharan G, Rivera RMC, Berry GE, Madigan VJ, Asokan A:  Mapping the structural determinants required for aavrh. 10 transport across the blood-brain  barrier. Molecular Therapy (2017).",
            "Bennett AD, Wong K, Lewis J, Tseng Y-S, Smith JK, Chipman P, McKenna R, Samulski RJ,  Kleinschmidt J, Agbandje-McKenna M: Aav6 k531 serves a dual function in selective receptor  and antibody adk6 recognition. Virology (2018) 518(369–376.",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]",
            "Zhong LI, Li B, Jayandharan G, Mah CS, Govindasamy L, Agbandje-McKenna M, Herzog RW,  Weigel-Van Aken KA, Hobbs JA, Zolotukhin S: Tyrosine-phosphorylation of aav2 vectors and its  consequences on viral intracellular trafficking and transgene expression. Virology (2008) 381(2): 194–202. [PubMed: 18834608]",
            "Gabriel N, Hareendran S, Sen D, Gadkari RA, Sudha G, Selot R, Hussain M, Dhaksnamoorthy R,  Samuel R, Srinivasan N: Bioengineering of aav2 capsid at specific serine, threonine, or lysine  residues improves its transduction efficiency in vitro and in vivo. Human gene therapy methods  (2013) 24(2):80–93. [PubMed: 23379478]"
        ],
        "AAV_terms": [
            "AAV",
            "AAV2",
            "AAV4",
            "AAV1",
            "AAV9",
            "AAVR",
            "AAVrh32",
            "AAVR-independent",
            "AAV2-based",
            "AAV8",
            "AAVrh",
            "AAV6",
            "AAV2G9",
            "AAV2i8G9",
            "AAV2i8",
            "AAV1RX"
        ],
        "PMCID": "PMC6516759",
        "PMID": "31106283"
    }
]